Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial.
- DOI
- 10.3390/vaccines11020326
- Published
- 2023 Feb 1
- Container
- Vaccines
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/vaccines11020326,
title = {Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial.},
author = {Kudriavtsev AV and Vakhrusheva AV and Kryuchkov NA and Frolova ME and Blagodatskikh KA and Ivanishin TV and Djonovic M and Romanovskaya-Romanko EA and Kovalenko AN and Lioznov DA and Zubkova TG and Teplykh SV and Oseshnyuk RA and Stukova MA and Isaev AA and Krasilnikov IV},
year = {2023},
journal = {Vaccines},
doi = {10.3390/vaccines11020326},
url = {https://doi.org/10.3390/vaccines11020326}
}RIS
TY - JOUR TI - Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial. AU - Kudriavtsev AV AU - Vakhrusheva AV AU - Kryuchkov NA AU - Frolova ME AU - Blagodatskikh KA AU - Ivanishin TV AU - Djonovic M AU - Romanovskaya-Romanko EA AU - Kovalenko AN AU - Lioznov DA AU - Zubkova TG AU - Teplykh SV AU - Oseshnyuk RA AU - Stukova MA AU - Isaev AA AU - Krasilnikov IV PY - 2023 JO - Vaccines DO - 10.3390/vaccines11020326 UR - https://doi.org/10.3390/vaccines11020326 ER -
APA
AV, K., AV, V., NA, K., ME, F., KA, B., TV, I., M, D., EA, R., AN, K., DA, L., TG, Z., SV, T., RA, O., MA, S., AA, I., & IV, K. (2023). Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial.. Vaccines. https://doi.org/10.3390/vaccines11020326
Source records
- pubmed · retrieved 2026-09-26T12:07:48.526Z